星空体育官方入口网站网址大全-登录入口官网

#ribociclib#

11篇内容 | 944人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1488591, encodeId=dd811488591ec, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效, objectType=article, longId=727632, objectId=94b4e2763255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b4e2763255, replyNumber=0, likeNumber=66, createdTime=2022-05-25, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b4e2763255, moduleTitle=BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=94b4e2763255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488590, encodeId=c9b6148859003, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=Clin Cancer Res：MONALEESA-7研究更新结果表明瑞博西尼（Ribociclib）联合内分泌治疗较内分泌单药持续改善HR+/HER2- 晚期乳腺癌患者的预后, objectType=article, longId=293536, objectId=393e293536fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=393e293536fe, replyNumber=0, likeNumber=62, createdTime=2022-01-08, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=393e293536fe, moduleTitle=Clin Cancer Res：MONALEESA-7研究更新结果表明瑞博西尼（Ribociclib）联合内分泌治疗较内分泌单药持续改善HR+/HER2- 晚期乳腺癌患者的预后, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=393e293536fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488589, encodeId=5cd814885896c, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性, objectType=article, longId=216493, objectId=e168216493b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e168216493b8, replyNumber=0, likeNumber=104, createdTime=2021-09-01, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e168216493b8, moduleTitle=Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e168216493b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488588, encodeId=4eca1488588ea, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, objectType=article, longId=213384, objectId=18202133844d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18202133844d, replyNumber=0, likeNumber=95, createdTime=2021-06-29, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18202133844d, moduleTitle=Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=18202133844d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488587, encodeId=575c148858ee7, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=65, createdTime=2021-06-29, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488586, encodeId=3d1014885865f, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=NICE：建议将Kisqali（ribociclib）与氟维司群联用，用于治疗局部晚期或转移性乳腺癌, objectType=article, longId=207679, objectId=6d4b20e679c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d4b20e679c7, replyNumber=0, likeNumber=65, createdTime=2021-02-28, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d4b20e679c7, moduleTitle=NICE：建议将Kisqali（ribociclib）与氟维司群联用，用于治疗局部晚期或转移性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d4b20e679c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488585, encodeId=237814885859c, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌, objectType=article, longId=200289, objectId=3ac1200289a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ac1200289a6, replyNumber=0, likeNumber=53, createdTime=2020-09-06, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ac1200289a6, moduleTitle=Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3ac1200289a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488584, encodeId=02481488584bf, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=NEJM：Ribociclib+氟维司群可改善晚期乳腺癌患者生存期, objectType=article, longId=184669, objectId=d9291846690b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9291846690b, replyNumber=0, likeNumber=72, createdTime=2019-12-14, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9291846690b, moduleTitle=NEJM：Ribociclib+氟维司群可改善晚期乳腺癌患者生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d9291846690b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488583, encodeId=6644148858347, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌, objectType=article, longId=139914, objectId=615f139914f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=615f139914f4, replyNumber=0, likeNumber=0, createdTime=2018-06-06, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=615f139914f4, moduleTitle=JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=615f139914f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488582, encodeId=b0e5148858282, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, objectType=article, longId=79630, objectId=1d17e9630e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d17e9630e6, replyNumber=0, likeNumber=46, createdTime=2016-10-11, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d17e9630e6, moduleTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1d17e9630e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488581, encodeId=8b5a14885814e, content=<a href='/topic/show?id=bc7a1545e44' target=_blank style='color:#2F92EE;'>#ribociclib#</a>, objectTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, objectType=article, longId=79604, objectId=a2e5e960448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e5e960448, replyNumber=0, likeNumber=74, createdTime=2016-10-10, rootId=0, userName=般若傻瓜, userId=2f558440263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e5e960448, moduleTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a2e5e960448)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ribociclib

2020-05-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

BMC Cancer：质子泵抑制剂(PPIs)可降低转移性乳腺癌患者使用palbociclib和 ribociclib治疗的疗效

2022-05-25

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

Clin Cancer Res：MONALEESA-7研究更新结果表明瑞博西尼（Ribociclib）联合内分泌治疗较内分泌单药持续改善HR+/HER2- 晚期乳腺癌患者的预后

2022-01-08

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性

2021-09-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

Ann Oncol: Ribociclib联合氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性：III期临床研究MONALEESA-3的结果更新

2021-06-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2021-06-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

NICE：建议将Kisqali（ribociclib）与氟维司群联用，用于治疗局部晚期或转移性乳腺癌

2021-02-28

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌

2020-09-06

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

NEJM：Ribociclib+氟维司群可改善晚期乳腺癌患者生存期

2019-12-14

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

JCO：Ribociclib联合Fulvestrant治疗激素受体阳性，HER2阴性晚期乳腺癌

2018-06-06

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）

2016-10-11

般若傻瓜 (审核中...)

前往app查看评论内容

#ribociclib#

NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期

2016-10-10

科室
- - 订阅+
  - 更多科室
工具
服务